medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-17-8-9medsovet-766Research ArticleНовостиNews. Findings and eventsХОБЛ: роль инфекционных обострений и их профилактикиCOPD: Role and prevention of infectious exacerbatonsШапороваН. Л.ShaporovaN. L.noemail@neicon.ruМарченкоВ. Н.MarchenkoV. N.noemail@neicon.ruЯблонскаяВ. Н.YablonskayаV. N.noemail@neicon.ruПервый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова Минздрава РоссииРоссияFirst Saint Petersburg State Medical University named after I.P. Pavlov, Russia’s Ministry of HealthRussian Federation20143012201401789Copyright © Шапорова Н.Л., Марченко В.Н., Яблонская В.Н., 20142014Шапорова Н.Л., Марченко В.Н., Яблонская В.Н.Shaporova N.L., Marchenko V.N., Yablonskayа V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/766

На ежегодной конференции Европейского общества медицинской онкологии - 2014, прошедшей осенью в Мадриде, были представлены новые данные по терапии местнораспространенного или метастазирующего рака молочной железы, а также прогрессирующего, рефрактерного к радиоактивному йоду дифференцированного рака щитовидной железы.

The article is a detailed review of current views on the incidence, causes and role of exacerbations in the progression of COPD, and the role of bacterial infection in exacerbations of the disease. Primary and secondary preventive actions are described. Antibacterial treatment approaches in patients with acute exacerbations of COPD are analyzed.

ХОБЛобострение ХОБЛантибактериальная терапияCOPDCOPD exacerbationsantibiotic therapyReferencesWHO. The World Health Report 2002. Reducing risks, promoting healthy life. MDI.WHR202.A. The World Health Organization, Geneva, 2002.WHO. The World Health Report 2002. Reducing risks, promoting healthy life. MDI.WHR202.A. The World Health Organization, Geneva, 2002.Murray CJ. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. C.J. Murray, A.D. Lopez. Lancet, 1997, 349: 1498-1504.Murray CJ. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. C.J. Murray, A.D. Lopez. Lancet, 1997, 349: 1498-1504.Lopez AD. Chronic obstructive pulmonary disease: current burden and future projections. A.D. Lopez , K. Shibuya, C. Rao et al. Eur Respir J., 2006, 27 (2): 188-207.Lopez AD. Chronic obstructive pulmonary disease: current burden and future projections. A.D. Lopez , K. Shibuya, C. Rao et al. Eur Respir J., 2006, 27 (2): 188-207.Pauwels RA. Burden and clinical features of chronic obstructive pulmonary disease (COPD). R.A. Pauwels, K.F. Rabe. Lancet, 2004, 364: 613-620.Pauwels RA. Burden and clinical features of chronic obstructive pulmonary disease (COPD). R.A. Pauwels, K.F. Rabe. Lancet, 2004, 364: 613-620.Donaldson GC Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. G.C. Donaldson, T.A. Seemungal, A. Bhowmik, J.A. Wedzicha. Thorax, 2002, 57: 847-852.Donaldson GC Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. G.C. Donaldson, T.A. Seemungal, A. Bhowmik, J.A. Wedzicha. Thorax, 2002, 57: 847-852.Seemungal T.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. T.A. Seemungal, G.C. Donaldson, E.A. Paul et al. Am] Respir Crit Care Med., 1998. 157: 1418-1422.Seemungal T.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. T.A. Seemungal, G.C. Donaldson, E.A. Paul et al. Am] Respir Crit Care Med., 1998. 157: 1418-1422.Miravitlles M. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. M. Miravitlles., C. Murio., T. Guerrero et al. Chest, 2002, 121: 1449-1455.Miravitlles M. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. M. Miravitlles., C. Murio., T. Guerrero et al. Chest, 2002, 121: 1449-1455.Gunen H. Factors affecting survival of hospitalized patients with COPD. H. Gunen, S.S. Hacievliyagil, F. Kosar et al. Eur Respir]., 2005, 26: 234-241.Gunen H. Factors affecting survival of hospitalized patients with COPD. H. Gunen, S.S. Hacievliyagil, F. Kosar et al. Eur Respir]., 2005, 26: 234-241.Soler-Cataluna JJ. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. J.J. Soler-Cataluna, M.A. Martinez-Garcia, P Roman Sanchez et al. Thorax 2005, 60: 925-931.Soler-Cataluna JJ. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. J.J. Soler-Cataluna, M.A. Martinez-Garcia, P Roman Sanchez et al. Thorax 2005, 60: 925-931.Wedzicha J.A. Exacerbations of chronic obstructive pulmonary disease. J.A. Wedzicha, G.C Donaldson. Respir Care. 2003, 48 (12): 1204-13.Wedzicha J.A. Exacerbations of chronic obstructive pulmonary disease. J.A. Wedzicha, G.C Donaldson. Respir Care. 2003, 48 (12): 1204-13.White AJ. Chronic obstructive pulmonary disease: 6. The aetiology of exacerbation of chronic obstructive pulmonary disease. AJ. White, S. Gompertz., R.A. Stockley. Thorax, 2003, 58: 73-80.White AJ. Chronic obstructive pulmonary disease: 6. The aetiology of exacerbation of chronic obstructive pulmonary disease. AJ. White, S. Gompertz., R.A. Stockley. Thorax, 2003, 58: 73-80.Gompertz S. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. S. Gompertz, C. O'Brien, D.L. Bayley et al. Eur Respir J., 2001, 17: 1112-1119.Gompertz S. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. S. Gompertz, C. O'Brien, D.L. Bayley et al. Eur Respir J., 2001, 17: 1112-1119.Cote CG. Impact of COPD Exacerbations on Patient-Centered Outcomes. C.G. Cote, L.J. Dordelly, B.R. Celli. Chest. 2007, 131: 696-704.Cote CG. Impact of COPD Exacerbations on Patient-Centered Outcomes. C.G. Cote, L.J. Dordelly, B.R. Celli. Chest. 2007, 131: 696-704.Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute; Update 2007, GOLD website (http://wwwgoldcopd.com).Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute; Update 2007, GOLD website (http://wwwgoldcopd.com).Дворецкий Л.И. Инфекционные обострения ХОБЛ. Л.И. Дворецкий. Лечащий врач, 2007, (3): 80-84.Дворецкий Л.И. Инфекционные обострения ХОБЛ. Л.И. Дворецкий. Лечащий врач, 2007, (3): 80-84.Anthonisen NR. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. N.R. Anthonisen, J. Manfreda, C.P Warren et al. Ann Intern. Med. 1987, 106: 196-204.Anthonisen NR. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. N.R. Anthonisen, J. Manfreda, C.P Warren et al. Ann Intern. Med. 1987, 106: 196-204.Wedzicha JA. Exacerbations of chronic obstructive pulmonary disease. J.A. Wedzicha, G.C. Donaldson. Respir Care. 2003, 48(12): 1204-1213.Wedzicha JA. Exacerbations of chronic obstructive pulmonary disease. J.A. Wedzicha, G.C. Donaldson. Respir Care. 2003, 48(12): 1204-1213.Monso E. Risk factors for lower airway bacterial colonization in chronic bronchitis. E. Monso, A. Rosell, G. Bonet et al. Eur Respir J, 1999, 13: 338-342.Monso E. Risk factors for lower airway bacterial colonization in chronic bronchitis. E. Monso, A. Rosell, G. Bonet et al. Eur Respir J, 1999, 13: 338-342.Soler N. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. N. Soler, S. Ewig, A. Torres et al. Eur Respir J, 1999, 14: 1015-1022.Soler N. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. N. Soler, S. Ewig, A. Torres et al. Eur Respir J, 1999, 14: 1015-1022.Patel IS. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. I.S. Patel, T.A. Seemungal, M. Wilks et al. Thorax 2002, 57: 759-764.Patel IS. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. I.S. Patel, T.A. Seemungal, M. Wilks et al. Thorax 2002, 57: 759-764.White AJ. The aetiology of exacerbations of chronic obstructive pulmonary disease. A.J. White, S. Gompertz, R.A. Stockle. Thorax, 2003, 58: 73-80.White AJ. The aetiology of exacerbations of chronic obstructive pulmonary disease. A.J. White, S. Gompertz, R.A. Stockle. Thorax, 2003, 58: 73-80.Monso E. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. E. Monso, J. Ruiz, J. Manterola et al. AmJ Respir Crit Care Med, 1995, 152: 1316-1320.Monso E. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. E. Monso, J. Ruiz, J. Manterola et al. AmJ Respir Crit Care Med, 1995, 152: 1316-1320.Lieberman D. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. D. Lieberman,. Lieberman D, M. Ben-Yaakov et al. Diagn Microbiol Infect Dis, 2002, 44 (1): 1-6.Lieberman D. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. D. Lieberman,. Lieberman D, M. Ben-Yaakov et al. Diagn Microbiol Infect Dis, 2002, 44 (1): 1-6.Lieberman D. Infectious etiologies in acute exacerbation of COPD. D. Lieberman, D. Lieberman, M. Ben-Yaakov et al. Diagn Microbiol Infect Dis 2001, 40: 95-102.Lieberman D. Infectious etiologies in acute exacerbation of COPD. D. Lieberman, D. Lieberman, M. Ben-Yaakov et al. Diagn Microbiol Infect Dis 2001, 40: 95-102.Soler N. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. N. Soler., A. Torres, S. Ewig et al. Am J Respir Crit Care Med, 1998, 157: 1498-1505.Soler N. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. N. Soler., A. Torres, S. Ewig et al. Am J Respir Crit Care Med, 1998, 157: 1498-1505.Eller J. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. J. Eller, A. Ede, T. Schaberg et al. Chest 1998, 113: 1542-1548.Eller J. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. J. Eller, A. Ede, T. Schaberg et al. Chest 1998, 113: 1542-1548.Papi A, Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations. A. Papi, C.M. Bellettato, F. Braccioni et al. Am J Respir Crit Care Med 2006, 173: 1114-1121.Papi A, Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations. A. Papi, C.M. Bellettato, F. Braccioni et al. Am J Respir Crit Care Med 2006, 173: 1114-1121.Tashkin D. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebocontrolled, randomised trial. D. Tashkin, R. Kanner, W. Bailey et al. Lancet 2001, 357 (9268): 1571-1575.Tashkin D. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebocontrolled, randomised trial. D. Tashkin, R. Kanner, W. Bailey et al. Lancet 2001, 357 (9268): 1571-1575.Casaburi R. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. R. Casaburi, D.D. Jr Briggs., J.F. Donohue et al. Chest. 2000, 118: 1294-1302.Casaburi R. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. R. Casaburi, D.D. Jr Briggs., J.F. Donohue et al. Chest. 2000, 118: 1294-1302.Vincken W. On behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1-yr's treatment with tiotropium. W. Vincken, J.A. van Noord, A.PM. Greefhorst et al. Eur Respir J, 2002, 19: 209-216.Vincken W. On behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1-yr's treatment with tiotropium. W. Vincken, J.A. van Noord, A.PM. Greefhorst et al. Eur Respir J, 2002, 19: 209-216.Barr RG. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. R.G. Barr, J. Bourbeau, C.A Camargo, FS.F Ram. Thorax 2006, 61: 854-862.Barr RG. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. R.G. Barr, J. Bourbeau, C.A Camargo, FS.F Ram. Thorax 2006, 61: 854-862.Alsaeedi A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. A. Alsaeedi, D.D. Sin, F.A. McAlister. Am J Med 2002, 113(1): 59-65.Alsaeedi A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. A. Alsaeedi, D.D. Sin, F.A. McAlister. Am J Med 2002, 113(1): 59-65.Gartlehner Effecacy and safety of inhaled corticosteroids in patients with COPD a systematic review and meta analysis of health outcomes. Gartlehner et al. AnnFam Med 2006, 4: 253-262.Gartlehner Effecacy and safety of inhaled corticosteroids in patients with COPD a systematic review and meta analysis of health outcomes. Gartlehner et al. AnnFam Med 2006, 4: 253-262.Wongsurakiat P Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. P Wongsurakiat, K.N. Maranetra, C. Wasi et al. Chest 2004, 125 (6): 2011-2020.Wongsurakiat P Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. P Wongsurakiat, K.N. Maranetra, C. Wasi et al. Chest 2004, 125 (6): 2011-2020.Alfageme R. Clinical efficiacy of anti-pneumococcal vaccination in patients with COPD. R Alfageme, R Vazquez, N. Reyes, et al. Thorax, 2006, 61: 189-195.Alfageme R. Clinical efficiacy of anti-pneumococcal vaccination in patients with COPD. R Alfageme, R Vazquez, N. Reyes, et al. Thorax, 2006, 61: 189-195.Decramer M. Chronic obstructive pulmonary disease. Seminar. M Decramer et al. Lancet, 2012, 379: 1341-1351.Decramer M. Chronic obstructive pulmonary disease. Seminar. M Decramer et al. Lancet, 2012, 379: 1341-1351.Woodhead M. Guidelines for the management of adult lower respiratory tract infections-full version. M. Woodhead et al. Clin Microbiol Infect, 2011, 17 (6): 1-59.Woodhead M. Guidelines for the management of adult lower respiratory tract infections-full version. M. Woodhead et al. Clin Microbiol Infect, 2011, 17 (6): 1-59.Козлов РС. Динамика резистентности Streptococcus pneumonia к антибиотикам в России за период 1999-2009 года (результаты многоцентрового проспективного исследования ПеГАС). Козлов РС. и соавт. Клин, микробиол. антимикроб. химиотер., 2010, 4: 329-341.Козлов РС. Динамика резистентности Streptococcus pneumonia к антибиотикам в России за период 1999-2009 года (результаты многоцентрового проспективного исследования ПеГАС). Козлов РС. и соавт. Клин, микробиол. антимикроб. химиотер., 2010, 4: 329-341.

The authors declare that there are no conflicts of interest present.